Insider Selling: Beta Bionics (NASDAQ:BBNX) Director Sells $147,890.00 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX) Director Christy Jones sold 6,430 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $23.00, for a total transaction of $147,890.00. Following the sale, the director directly owned 19,564 shares of the company’s stock, valued at approximately $449,972. This represents a 24.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beta Bionics Stock Down 1.1%

Shares of NASDAQ BBNX opened at $21.51 on Friday. Beta Bionics, Inc. has a 12 month low of $8.80 and a 12 month high of $32.71. The company has a market cap of $967.73 million, a price-to-earnings ratio of -13.04 and a beta of 3.37. The business has a fifty day simple moving average of $18.17 and a 200-day simple moving average of $14.42.

Beta Bionics (NASDAQ:BBNX) last issued its earnings results on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The business had revenue of $32.01 million during the quarter. As a group, sell-side analysts expect that Beta Bionics, Inc. will post -2.06 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on BBNX. Leerink Partners upped their price target on shares of Beta Bionics from $24.00 to $27.00 and gave the company an “outperform” rating in a report on Monday, September 14th. Wells Fargo & Company started coverage on Beta Bionics in a research note on Wednesday. They issued an “overweight” rating and a $28.00 price objective on the stock. Truist Financial boosted their price objective on Beta Bionics from $23.00 to $28.00 and gave the stock a “buy” rating in a research report on Thursday. Bank of America increased their target price on Beta Bionics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Tuesday, September 15th. Finally, The Goldman Sachs Group raised their target price on Beta Bionics from $17.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Eight equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Beta Bionics currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.91.

Hedge Funds Weigh In On Beta Bionics

A number of hedge funds have recently modified their holdings of BBNX. Eventide Asset Management LLC grew its stake in Beta Bionics by 0.8% during the fourth quarter. Eventide Asset Management LLC now owns 4,994,728 shares of the company’s stock worth $152,233,000 after buying an additional 37,476 shares during the last quarter. BlackRock Inc. bought a new position in shares of Beta Bionics in the second quarter valued at approximately $52,340,000. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Beta Bionics in the fourth quarter valued at approximately $40,437,000. Eversept Partners LP acquired a new position in shares of Beta Bionics in the 4th quarter worth approximately $20,667,000. Finally, 12 West Capital Management LP acquired a new position in shares of Beta Bionics in the 4th quarter worth approximately $17,520,000.

Key Stories Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Truist Financial raised its price target on Beta Bionics to $28 from $23 and maintained a “Buy” rating, implying meaningful upside from recent trading levels. Wells Fargo also initiated coverage with an “Overweight” rating and a $28 target, while other analysts have recently raised their targets. Truist Financial rating
• Neutral Sentiment: Multiple law firms publicized a securities class action against Beta Bionics on behalf of investors who purchased shares between July 30, 2025, and February 24, 2026. The lead-plaintiff deadline is November 3, 2026; the repeated notices are mostly informational but increase attention on the company’s legal situation. Kaplan Fox class action notice
• Negative Sentiment: The lawsuits allege that Beta Bionics failed to adequately disclose FDA concerns, including a 2025 Form 483 and more than 18,000 iLet-related complaints. The allegations link later disclosures about FDA compliance and device safety to a sharp share-price decline. They have not been proven, but could create financial, operational and reputational uncertainty. BFA Law BBNX investor alert
• Negative Sentiment: Director Christy Jones sold 6,430 shares for approximately $147,890, reducing her position by about 24.7%. The sale occurred under a pre-arranged Rule 10b5-1 plan, which makes it a less definitive bearish signal, but it nevertheless adds to investor caution. SEC insider sale filing

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.